Compounds > n,n'-diacetylbenzidine
Page last updated: 2024-12-05

n,n'-diacetylbenzidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N,N'-diacetylbenzidine: induces glomerular epithelial cell lesions; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11942
CHEMBL ID1567221
CHEBI ID82308
SCHEMBL ID3818831
MeSH IDM0050393

Synonyms (74)

Synonym
CBDIVE_014211
HMS2587G07
n,n'-diacetylbenzidine
n,4'-biphenylylenebisacetamide
613-35-4
acetamide,n'-[1,1'-biphenyl]-4,4'-diylbis-
acetamide,n'-4,4'-biphenylylenebis-
nsc-4717
diacetylbenzidine
4,4'-diacetamidobiphenyl
benzidine,n'-diacetyl-
4,4'-diacetylaminobiphenyl
wln: 1vmr dr dmv1
nsc4717
n,1'-biphenyl)-4,4'-diylbis-acetamide
4,4'-diacetylbenzidine
4',4'''-biacetanilide
acetamide, n,n'-[1,1'-biphenyl]-4,4'-diylbis-
n,n'-diacetyl benzidine
n-[4'-(acetylamino)-1,1'-biphenyl-4-yl]acetamide
MLS000682798
smr000312155
nsc 12409
brn 2217711
biphenyl, 4,4'-diacetamido-
n,n'-(1,1'-biphenyl)-4,4'-diylbisacetamide
n,n'-4,4'-biphenylylenebisacetamide
benzidine, n,n'-diacetyl-
ai3-08917
ccris 197
nsc 4717
acetamide, n,n'-4,4'-biphenylylenebis-
acetamide, n,n'-(1,1'-biphenyl)-4,4'-diylbis-
n,n'-(1,1'-biphenyl)-4,4'-diylbis-acetamide
hsdb 5078
einecs 210-338-2
n,n'-(1,1'-biphenyl)-4,4'-diylbis-acetamide 4',4'''-biacetanilide
nsc12409
nsc-12409
OPREA1_870996
OPREA1_734946
MAYBRIDGE4_003199
NCGC00176103-01
n,n'-biphenyl-4,4'-diyldiacetamide
STK122403
HMS1530B09
AKOS000495581
n-[4-(4-acetamidophenyl)phenyl]acetamide
C19217
unii-2ee5599gqs
4-13-00-00373 (beilstein handbook reference)
2ee5599gqs ,
FT-0632558
diacetylbenzidine, n,n-
4,4'-diacetylbenzidine [hsdb]
n,n'-diacetylbenzidine [iarc]
CHEBI:82308 ,
CHEMBL1567221
SCHEMBL3818831
n-[4'-(acetylamino)[1,1'-biphenyl]-4-yl]acetamide #
CZVHCFKUXGRABC-UHFFFAOYSA-N
4,4'-diacetylamino-1,1'-biphenyl
n-(4'-acetylamino-biphenyl-4-yl)-acetamide
DTXSID9036854
sr-01000596885
SR-01000596885-1
mfcd00048194
4,4-bis(methoxycarbonyl)-2,2-bipyridine
n,n'-(biphenyl-4,4'-diyl)diacetamide
Q26840865
n,n'-([1,1'-biphenyl]-4,4'-diyl)diacetamide
CS-0362407
n,n'-[1,1'-biphenyl]-4,4'-diylbis-acetamide
n-{4'-acetamido-[1,1'-biphenyl]-4-yl}acetamide

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" A preliminary dose-response test showed that NOHDABZ was the most toxic compound; it caused chemical peritonitis and death in each of 4 animals given 70 mumol/kg body weight/injected."( Carcinogenicity of benzidine, N,N'-diacetylbenzidine, and N-hydroxy-N,N'-diacetylbenzidine for female CD rats.
Garner, CD; Morton, KC; Shirai, T; Wang, CY, 1981)		0.55
" The nonspecific cytochrome P450 inhibitor SKF-525A (10 microM) exhibited a partial dose-response inhibition (maximum 41% of complete reaction mixture) of N'HA formation, but did not alter NHA formation."( Rat liver cytochrome P450 metabolism of N-acetylbenzidine and N,N'-diacetylbenzidine.
Davis, BB; Lakshmi, VM; Zenser, TV, 1997)		0.54
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
biphenylsBenzenoid aromatic compounds containing two phenyl or substituted-phenyl groups which are joined together by a single bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
WRNHomo sapiens (human)Potency39.81070.168331.2583100.0000AID651768
ATAD5 protein, partialHomo sapiens (human)Potency29.08100.004110.890331.5287AID504467
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency20.59620.00419.984825.9290AID504444
huntingtin isoform 2Homo sapiens (human)Potency1.99530.000618.41981,122.0200AID1688
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
lethal(3)malignant brain tumor-like protein 1 isoform IHomo sapiens (human)Potency14.12540.075215.225339.8107AID485360
survival motor neuron protein isoform dHomo sapiens (human)Potency15.84890.125912.234435.4813AID1458
DNA dC->dU-editing enzyme APOBEC-3F isoform aHomo sapiens (human)Potency6.30960.025911.239831.6228AID602313
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (20)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (50.00)18.7374
1990's2 (10.00)18.2507
2000's2 (10.00)29.6817
2010's5 (25.00)24.3611
2020's1 (5.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.36

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.36 (24.57)
Research Supply Index3.14 (2.92)
Research Growth Index4.50 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.36)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
beta-naphthoflavone
beta-Naphthoflavone: A polyaromatic hydrocarbon inducer of P4501A1 and P4501A2 cytochromes. (Proc Soc Exp Biol Med 1994 Dec:207(3):302-308). beta-naphthoflavone : An extended flavonoid resulting from the formal fusion of a benzene ring with the f side of flavone.		1.9910extended flavonoid;
naphtho-gamma-pyrone;
organic heterotricyclic compound		aryl hydrocarbon receptor agonist
proadifen
Proadifen: An inhibitor of drug metabolism and CYTOCHROME P-450 ENZYME SYSTEM activity.		1.9910diarylmethane
desoxycorticosterone
Desoxycorticosterone: A steroid metabolite that is the 11-deoxy derivative of CORTICOSTERONE and the 21-hydroxy derivative of PROGESTERONE		1.961020-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
mineralocorticoid;
primary alpha-hydroxy ketone		human metabolite;
mouse metabolite
benzidine
benzidine: RN given refers to parent cpd. benzidine : A member of the class of biphenyls that is 1,1'-biphenyl in which the hydrogen at the para-position of each phenyl group has been replaced by an amino group.		2.8940biphenyls;
substituted aniline		carcinogenic agent
direct blue 6
[no description available]		1.9610
n-acetylbenzidine
[no description available]		3.3670
acetyl coenzyme a
Acetyl Coenzyme A: Acetyl CoA participates in the biosynthesis of fatty acids and sterols, in the oxidation of fatty acids and in the metabolism of many amino acids. It also acts as a biological acetylating agent.		1.9610acyl-CoAacyl donor;
coenzyme;
effector;
fundamental metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510
Encephalitis, Polio
[description not available]		02.0610
Poliomyelitis
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)		02.0610
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		01.9610
Experimental Neoplasms
[description not available]		01.9610
Autoimmune Disease
[description not available]		02.3620
Hypertension, Renal
Persistent high BLOOD PRESSURE due to KIDNEY DISEASES, such as those involving the renal parenchyma, the renal vasculature, or tumors that secrete RENIN.		01.9610
Nephritis
Inflammation of any part of the KIDNEY.		02.3620
Autoimmune Diseases
Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.		02.3620
Kidney Diseases
Pathological processes of the KIDNEY or its component tissues.		01.9610
Proteinuria
The presence of proteins in the urine, an indicator of KIDNEY DISEASES.		02.3620
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		01.9610
Hypersensitivity, Type III
[description not available]		01.9610
Nephrosis
Pathological processes of the KIDNEY without inflammatory or neoplastic components. Nephrosis may be a primary disorder or secondary complication of other diseases. It is characterized by the NEPHROTIC SYNDROME indicating the presence of PROTEINURIA and HYPOALBUMINEMIA with accompanying EDEMA.		01.9610
Kidney, Polycystic
[description not available]		01.9510
Ascites
Accumulation or retention of free fluid within the peritoneal cavity.		01.9510
Polycystic Kidney Diseases
Hereditary diseases that are characterized by the progressive expansion of a large number of tightly packed CYSTS within the KIDNEYS. They include diseases with autosomal dominant and autosomal recessive inheritance.		01.9510
Nephrotic Syndrome
A condition characterized by severe PROTEINURIA, greater than 3.5 g/day in an average adult. The substantial loss of protein in the urine results in complications such as HYPOPROTEINEMIA; generalized EDEMA; HYPERTENSION; and HYPERLIPIDEMIAS. Diseases associated with nephrotic syndrome generally cause chronic kidney dysfunction.		01.9510